Клобазам: Бензодиазепиновый препарат для лечения эпилепсии и тревоги.

Benzodiazepine class medication

Clobazam, sold under the brand names Frisium, Onfi and others, is a benzodiazepine class medication that was patented in 1968. Clobazam was first synthesized in 1966 and first published in 1969. Clobazam was originally marketed as an anxioselective anxiolytic since 1970, and an anticonvulsant since 1984. The primary drug development goal was to provide greater anxiolytic, anti obsessive efficacy with fewer benzodiazepine related side effects. It is not recommended for use in children between the ages of six months and three years, unless there is a compelling need. Clobazam is sometimes used for refractory epilepsies. However, long term prophylactic treatment of epilepsy may have considerable drawbacks, most importantly decreased antiepileptic effects due to drug tolerance which may render long term therapy less effective. Other antiepileptic drugs may therefore be preferred for the long term management of epilepsy. Furthermore, benzodiazepines may have the drawback, particularly after long term use, of causing rebound seizures upon abrupt or over rapid discontinuation of therapy forming part of the benzodiazepine withdrawal syndrome. Clobazam is approved in Canada for add on use in tonic clonic, complex partial, and myoclonic seizures. Clobazam is approved for adjunctive therapy in complex partial seizures, certain types of status epilepticus, specifically the myoclonic, myoclonic absent, simple partial, complex partial, and tonic varieties, and non status absence seizures. It is also approved for the treatment of anxiety. In India, clobazam is approved for use as an adjunctive therapy in epilepsy, and in acute and chronic anxiety. In Japan, clobazam is approved for adjunctive therapy in treatment resistant epilepsy featuring complex partial seizures. In New Zealand, clobazam is marketed as Frisium In the United Kingdom clobazam (Frisium) is approved for short term (2–4 weeks) relief of acute anxiety in patients who have not responded to other drugs, with or without insomnia and without uncontrolled clinical depression. It was not approved in the United States until 25 October 2011, when it was approved for the adjunctive treatment of seizures associated with Lennox Gastaut syndrome in patients 2 years of age or older. The current FDA indicated for use in combination with other medicines is to control seizures in adults and children 2 years and older who have a specific severe form of epilepsy called Lennox Gastaut syndrome. Clobazam has been FDA approved for 12 years as of 2023 and it is available in multiple formulations under the brand names Onfi and Sympazan as well as generic formulations.

In September 2020, the U. S. Food and Drug Administration (FDA) required the boxed warning be updated for all benzodiazepine medicines to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.

Common side effects include fever, drooling, and constipation.

Hives. Rashes.

In December 2013, the FDA added warnings to the label for clobazam, that it can cause serious skin reactions, Stevens–Johnson syndrome, and toxic epidermal necrolysis, especially in the first eight weeks of treatment.

Alcohol increases bioavailability by 50%; compounded depressant effect may precipitate life threatening toxicity. Cimetidine increases the effects of clobazam. Valproate.

Overdose and intoxication with benzodiazepines, including clobazam, may lead to CNS depression, associated with drowsiness, confusion, and lethargy, possibly progressing to ataxia, respiratory depression, hypotension, and coma or death. The risk of a fatal outcome is increased in cases of combined poisoning with other CNS depressants, including alcohol.

Classic (non anxioselective) benzodiazepines in animal studies have been shown to increase reward seeking behaviours which may suggest an increased risk of addictive behavioural patterns. Clobazam abuse has been reported in some countries, according to a 1983 World Health Organisation report.

In humans, tolerance to the anticonvulsant effects of clobazam may occur and withdrawal seizures may occur during abrupt or over rapid withdrawal. Clobazam as with other benzodiazepine drugs can lead to physical dependence, addiction, and what is known as the benzodiazepine withdrawal syndrome. Withdrawal from clobazam or other benzodiazepines after regular use often leads to withdrawal symptoms which are similar to those seen during alcohol and barbiturate withdrawal. The higher the dosage and the longer the drug is taken, the greater the risk of experiencing unpleasant withdrawal symptoms. Benzodiazepine treatment should only be discontinued via a slow and gradual dose reduction regimen.

Clobazam is predominantly a positive allosteric modulator at the GABAA receptor with some speculated additional activity at sodium channels and voltage sensitive calcium channels. Like other 1,5 benzodiazepines (for example, arfendazam, lofendazam, or CP 1414S), the active metabolite N desmethylclobazam has less affinity for the α1 subunit of the GABAA receptor compared to the 1,4 benzodiazepines. It has higher affinity for α2 containing receptors, where it has positive modulatory activity. In a double blind placebo controlled trial published in 1990 comparing it to clonazepam, 10 mg of clobazam was shown to be less sedative than either 0.5 mg or 1 mg of clonazepam. The α1 subtype of the GABAA receptor, was shown to be responsible for the sedative effects of diazepam by McKernan et al. in 2000, who also showed that its anxiolytic and anticonvulsant properties could still be seen in mice whose α1 receptors were insensitive to diazepam. In 1996, Nakamura et al. reported that clobazam and its active metabolite, N desmethylclobazam (norclobazam), work by enhancing GABA activated chloride influx at GABAA receptors, It was also reported that these effects were inhibited by the GABA antagonist flumazenil, and that clobazam acts more efficiently in GABA deficient brain tissue.

Clobazam has two major metabolites: N desmethylclobazam and 4′ hydroxyclobazam, the former of which is active. The demethylation is facilitated by CYP2C19, CYP3A4, and CYP2B6 and the 4 hydroxyclobazam by CYP2C18 and CYP2C19. In children, clobazam half life values is average 16 hours, while in the elderly, clobazam half life values are 30 to 48 hours.

Clobazam is a 1,5 benzodiazepine, meaning that its diazepine ring has nitrogen atoms at the 1 and 5 positions (instead of the usual 1 and 4). It is not soluble in water and is available in oral form only. Maestretti was acquired by Roussel Uclaf which became part of Sanofi.